Targeting Metastases

To prevent cancer recurrence and progression after primary tumour therapy.

Product Development

News

Dec 04, 2019–RhoVac recruits Steffen Wad Jørgensen as Chief Development Officer (regulatory)Dec 02, 2019–RhoVac ends the collaboration with Colpman Consulting Ltd (regulatory)Nov 18, 2019–RhoVac reports interim results on immunological response with RV001 (regulatory)

BioStock, interview with CEO Anders Månsson (in Swedish)

New Corporate Video